Anbio Biotechnology (NNNN) income statement
NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.60−0.05 (-1.37%)
Close on Nov 18, 2026Market cap $518.01MP/E 24.5Yield –
Anbio Biotechnology income statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, FY2025
- Gross margin
- 87.2%
- Operating margin
- 66.7%
- Net margin
- 74.1%
- Return on equity, FY2025
- 27.0%
Financial strength
- Current ratio
- 344.31
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 8842.3%
Valuation
- P/E ratio
- 24.5
- Price to sales
- 59.91
- Price to book
- 17.18
- Dividend yield
- –
See a number that looks wrong?